A pproximately 5.1 million people in the United States are currently diagnosed with heart failure (HF). 1 The prevalence of HF is projected to increase 25% by 2030 with the cost of its hospitalizations increase by 120% to ≈70 billion dollars/ yr. Blacks are at a greater risk for HF and also have higher HF-related morbidity and mortality compared with whites. [2] [3] [4] However, the underlying reason for such disparity is not clearly understood. Aside from a higher prevalence of medical comorbidities, such as hypertension and diabetes mellitus, in blacks, 5 nutritional factors, such as magnesium intake, may be related to HF incidence or recurrence but yet unproven, which would be of paramount importance for the prevention of HF in the population.
Magnesium Intake and Heart Failure Hospitalizations in the Jackson Heart Study (JHS), the largest black cohort to date for the study of cardiovascular disease.
Methods
We conducted a longitudinal analysis to evaluate the relationship of magnesium intake (including dietary and oral supplements) and HF hospitalizations in black participants of the JHS. We also sought to determine whether magnesium intake is related to LV systolic or diastolic function, as determined by echocardiography, as potential mechanisms in the development of HF. The JHS protocol was approved by the University of Mississippi Medical Center Institutional Review Board, and the participants provided written informed consent. The current analysis of the JHS data was approved by the JHS Publication and Presentations Subcommittee and exempted from ongoing review by the Providence VA Medical Center Institutional Review Board given deidentified data hosted at the institution.
Population
The JHS is a population-based, prospective study designed to evaluate the pathogenesis of cardiovascular disease among blacks residing in a tri-county metropolitan area (Hinds, Madison, Rankin Counties) in central Mississippi. 12 The JHS study sample (n=5301) was recruited between 2000 and 2004 and was drawn from predominantly 3 sources that targeted adults aged 21 to 95 years. 13 The first recruitment sample (age 55-74 years) accounted for ≈30% of the full JHS cohort and was from the Jackson Field Center of the Atherosclerosis Risk in Communities (ARIC) Study. The second recruitment source, 39% of the full JHS cohort, was a community sample (age 35-84 years) from a commercially available list of all residents and volunteers identified through participant referral or outreach activities for which recruitment was distributed among defined demographic cells in proportions designed to mirror those in the overall population. The third recruitment source, ≈31% of the full JHS cohort, was from relatives of JHS index participants (age >21 years).
During the baseline visit, subjects answered questionnaires and underwent clinical examination and echocardiographic evaluation. Individuals were included in this analysis if they completed a validated 158-item Food-Frequency Questionnaire (FFQ) during the baseline visit (n=5133). 14 
Exposure
Elements of oral intake were assessed by means of a validated 158item FFQ administered face-to-face by trained black interviewers. 14 The FFQ was adapted and validated 14, 15 from a longer, 283-item FFQ developed using data from 2 individual, 24-hour recalls collected from a representative sample of adults living in the Mississippi Delta region 16 (r= 0.60 for men and 0.55 for women between the 158-item FFQ and the mean of four 24-hour dietary recalls). Total daily magnesium intake was calculated from the contributions of each of the 158 food items and from the use of common vitamin and mineral supplement formulations. Daily magnesium intake was divided by body weight (kg) to account for individual's distinct magnesium body storage capacity (bones and soft tissue) and stratified by quartiles (0.522-2.308, 2.309-3.147, 3.148-4.226, and ≥4.227 mg magnesium intake/kg). 17
Outcomes
The main outcome was time to first adjudicated probable or definite HF hospitalization or death during 2005-2010. 18 The definition of HF hospitalization was developed by the congestive HF working group at the JHS based on the modification of the Multiethnic Study of Atherosclerosis, 19 Framingham, 20, 21 and Cardiovascular Health Study (patient symptoms, physician physical findings, and diagnostic procedures). 22 Adjudication of HF hospitalizations was performed by trained and certified HF abstractors and began on January 1, 2005. The criteria for HF hospitalization were (1) a discharge diagnosis International Classification of Disease-Ninth Revision code of 428 or underlying cause of death of I50; and (2) radiographic findings consistent with congestive HF, physical findings of increased venous pressure >16 mm Hg, or dilated ventricle/ LV function <40% by echocardiogram/multiple-gated acquisition scan; or (3) autopsy finding of pulmonary edema/congestive HF.
Echocardiographic Parameters
Given that echocardiographic parameters reflect potential underlying pathophysiologic pathways linking magnesium intake to HF, these parameters were analyzed separately from the demographic and clinical variables to explore the association of echocardiographic parameters (LV systolic and diastolic function) with quartiles of total magnesium intake/kg of body weight. Detailed echocardiography procedures are available online. 23 Briefly, echocardiograms were recorded by trained sonographers and interpreted by experienced cardiologists in the Echocardiography Reading Center located at the University of Mississippi Medical Center, who were blinded to the participants' clinical data. 24 All measurements were performed on 2-dimensional images, and no tissue Doppler was performed. LV mass was indexed to height to adjust for body habitus. LV systolic function was assessed with EF, and in the absence of availability of contemporary Doppler indices to grade diastolic dysfunction, 25 we chose transmitral early (E) filling velocity that reflect the LA-LV pressure gradients in early diastole as a surrogate for diastolic function. Tricuspid regurgitation peak velocity was used to estimate pulmonary artery systolic pressures.
Covariates
Coronary heart disease was considered present when the participant reported a history of myocardial infarction, abnormal stress test, prior coronary artery bypass graft surgery, or prior coronary angioplasty. The presence of diabetes mellitus was defined as a self-reported history of diabetes mellitus, use of diabetes mellitus medications, hemoglobin A1c ≥6.5, or a fasting blood glucose ≥7 mmol/L (126 mg/ dL). Heart rate was measured at the baseline ECG. History of HF was considered present if the patient responded affirmatively to the question "Has a doctor ever said you had HF or congestive HF?" at the time of first annual telephone follow-up between 2001 and 2005 before the HF hospitalization outcome ascertainment. Cigarette smoking was categorized as never smoker (having smoked <400 cigarettes in one's life), former smoker (smoked >400 cigarettes but not currently smoking), and current smoker. Blood pressure-lowering medication use was ascertained at the baseline clinical examination. Antihypertensive medications were categorized into the following classes: α-adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-adrenergic blockers, calcium channel blockers, thiazide diuretics, loop diuretics, and potassiumsparing diuretics. Infrequently prescribed medications were classified as Others, ie vasodilators, centrally acting α-agonists, and Rauwolfia derivatives. Total daily protein, phosphorous, alcohol, calcium, potassium, and caloric intake were calculated from the contributions of each of the 158 food items and dietary supplements.
Statistical Analysis
We excluded participants missing magnesium intake information from the FFQ (n=164) and baseline weight (n=7). We also excluded participants with improbable daily energy intakes (≤400 kcal or ≥10 000 kcal [n=15]). Patients were also removed from the analysis if they were lost to follow-up or died before the first adjudicated HF date on January 1, 2005 (n=199), leaving a total of 4916 (92.7%) participants for analysis ( Figure 1 ). We computed descriptive statistics and tested for linearity trend for demographic characteristics, health behaviors, baseline comorbidities, and echocardiographic parameters across dietary magnesium intake/kg quartiles.
We used Cox proportional hazards modeling to study the association between quartiles of dietary magnesium intake/kg with HF hospitalization adjusting for variables used in the ARIC HF prediction model (age, sex, coronary heart disease, body mass index, diabetes mellitus, systolic blood pressure, blood pressure medication use, heart rate, and smoking status) 26 and dietary measures influencing intestinal magnesium absorption and excretion, such as intake of phosphorus, 27 protein, 28, 29 and alcohol, 30 using the lowest dietary magnesium intake/kg quartile as the reference category (0.522-2.308 mg/kg). Adjustment for alcohol intake was made as chronic alcohol consumption increases urinary magnesium excretion and reduces total muscle magnesium content. 30 Race was part of the ARIC model but was dropped because our population was exclusively black. Our result model has excellent discrimination for the study population (Harrell C=0.84) and adequate calibration. Kaplan-Meier curves were created to estimate freedom from HF hospitalization according to dietary magnesium intake/kg quartiles. We tested the proportionality of hazards assumption for the Kaplan-Meier curves by visual inspection and analysis of the Schoenfeld residuals. 31 The proportional hazards assumption was confirmed for the primary analysis (P=0.66). Subjects during the study period that died before an HF event were censored. To confirm that censoring participants that died did not significantly alter the hazards of HF hospitalization (main outcome), we repeated our analysis by estimating the subhazard ratios using the competing risks regression model, according to the method of Fine and Gray. 32 We repeated our analyses excluding individuals with previously diagnosed HF (n=138) or did not report HF status (n=254) to ensure that our estimates are not driven mostly by individuals with diagnosed HF. Because HF hospitalization risk may vary by sex, diabetes mellitus status, and systolic function (≤55% versus >55%), effect modification analyses using multiplicative terms were conducted to determine whether subgroup analyses should be performed. In addition, as magnesium intake may just be a marker for the intake of healthy foods that also contain nutrients, such as potassium and calcium content, for total amount of caloric intake, or for a distinct annual income status, we conducted sensitivity analyses adjusting for these variables. Furthermore, because as much as 10% of dietary intake may be derived from the hardness of water and water magnesium concentrations were not available, we conducted an analysis adjusting for the total amount of daily water intake. Sensitivity analyses were also conducted using both quartiles of magnesium intake (without kilogram of body mass) and the logarithmically transformed magnesium intake, with and without division for kilogram of body mass, as the main exposures, to obtain nonweight-adjusted and continuous estimates of magnesium intake, respectively, and their association with hospitalization risk. Given that significant differences in dietary patterns and family income status were found between subjects from the 3 sources of JHS recruitment strategy (ARIC participants, n=1749; community volunteers, n=2059; and JHS participant's relatives, n=1108; Table I in the Data Supplement), sensitivity analyses of subgroups stratified by recruitment strategy were also conducted. Further analyses adjusting for clustering by family were conducted for JHS participants who were identified as being family members (includes the relatives cohort and participants from other recruitment sources, n=1535) because family members may share similar genetic predisposition, dietary habits, and health behaviors.
Data were 75.9% complete for all covariates included in the model. Missing data ranged from 0.18% (heart rate) to 18.4% (blood pressure medication use). Missing data were imputed based on 5 sets of simulated values generated from nonmissing variables using the multiple imputation method in STATA (StataCorp, College Station, TX). 33 Analyses were performed on each of the 5 data sets completed with imputed values and then combined using Rubin's combination rules to consolidate the individual estimates into a single set of estimates using the MI estimate command in STATA. 34 Sensitivity analyses were also repeated without imputation of missing variables. All analyses were performed using STATA/SE version 11.2 software (StataCorp LP). A 2-sided P value of <0.05 was considered significant.
Results

Baseline Characteristics of the Study Cohort
Of the 5115 subjects that completed the 158-item FFQ, we have follow-up information on HF admission starting on January 1, 2005, on 4916 participants. Excluded participants (7.3% of the original sample) had higher intakes of total daily energy, protein, alcohol, phosphorous water, potassium, calcium, and magnesium. Excluded participants were also more likely to be a current smoker and to have a history of COPD, stroke, coronary heart disease, or diabetes mellitus (Table II in the Data Supplement). The median gap from the baseline visit to initiation of HF adjudication was 816 days (275-1526 days). The median follow-up time starting January 1, 2005, was 1837 days (4-2190 days). A total of 270 individuals had a confirmed HF hospitalization during the follow-up period. The incidence of HF admission during follow-up was 1.1% per person-year during the adjudication period.
The baseline clinical characteristics of the study population, both overall and according to magnesium intake/kg quartiles, are shown in Table 1 . The overall study cohort had a mean age of 55.4 (SD, 12.7 years), of which 63.8% were women, 21.7% had diabetes mellitus, 61.4% hypertension, and 7.1% had coronary heart disease. Compared with the participants in the lowest quartile, participants in the higher quartiles of dietary magnesium intake/kg were more likely to be male, to have higher high-density lipoprotein-cholesterol, and to have total daily energy intake, despite having lower body mass index. They also had higher intake of protein, alcohol, water, calcium, potassium, and phosphorus and were more likely to be a current smoker. Participants in the lowest dietary magnesium intake/kg quartile, on the contrary, were more likely to have diabetes mellitus, hypertension and higher glycosylated hemoglobin A1c, and high-sensitivity C-reactive protein (hsCRP). Those in the lowest quartile were also more likely to report taking antihypertensive or diuretic medications than those participants in the higher quartiles. 
HF Hospitalizations
When compared with participants in the first quartile of magnesium intake/kg, those in the higher quartiles of magnesium intake/kg had lower unadjusted hazard ratios of HF admission starting with intake levels in the second quartile (2.308 mg magnesium intake/kg of weight) and higher. Figure 2 shows the unadjusted Kaplan-Meier survival curves of participants grouped by the quartiles of dietary magnesium intake/kg. After adjustment for potential confounding (model 1; Table 2 ), the adjusted hazard ratios of HF admission for subjects with magnesium intake in the second quartile or higher were lower, ranging from 0.66 (95% confidence interval, 0.47-0.94) in the second quartile to 0.47 (95% confidence interval, 0.27-0.82) in the fourth quartile, compared with individuals in the lowest quartile of magnesium intake/kg ( Kaplan-Meier survival estimates *Model 1: Adjusted for age, sex, heart rate, systolic blood pressure, smoking status, body mass index, blood pressure medication, history of diabetes mellitus, history of coronary heart disease, history of heart failure, total daily intake of protein, alcohol, and phosphorous. †Model 2: Model 1 and baseline ejection fraction levels (220 subjects with missing ejection fraction data). ‡Model 3: Model 1 and total daily water intake. §Model 4: Model 1 and total daily potassium intake. ║Model 5: Model 1 and total daily calcium intake. ¶Model 6: Model 1 and total daily energy intake. #Model 7: Model 1 and socioeconomic status.
(model 6), and family annual income (model 7; Table 2 ). Confirmatory analyses using the competing risks regression model by estimating the subhazard ratios of HF in the presence of a competing event (death) showed similar results. Effect modification analyses using multiplicative terms for sex, EF, and diabetes mellitus diagnosis were nonsignificant, for which subgroup analyses were not pursued.
Sensitivity Analyses
Using Cox regression modeling to study the relation between quartiles of magnesium intake without accounting for kilogram of body weight and HF hospitalizations yielded similar results even when adjusted for daily energy intake (model 6; Table 2 ). Results remained unchanged when individuals with previous diagnosed HF (2.8%) and those who did not report HF status were excluded ( Table 2) . Analyses using the logarithmically transformed dietary magnesium intake (with and without division for kilogram) as a continuous variable did not show a significant linear relationship between magnesium intake and HF hospitalizations (adjusted hazard ratio for log magnesium intake/kg=0.73; 95% confidence interval, 0.45-1.20; P=0.21; and for log magnesium intake accounting for caloric intake=0.65; 95% confidence interval, 0.39-1.10; P=0.11). Both nonimputed and imputed sensitivity analyses results were similar. Analyses in subgroups stratified by recruitment strategy and among JHS participants who are identified as family members, adjusting for clustering by the family identification variable, showed similar results ( Table III in the Data Supplement) . Table 3 shows the echocardiographic parameters of the study cohort. The mean EF of the study cohort was 61.7±7.7%, with a relatively high overall prevalence of a normal EF (92.5% with EF ≥55%). Compared with the participants in the lowest quartile of magnesium intake/kg, participants across quartiles of magnesium intake/kg had similar LV mass and EF values. However, Doppler peak mitral E-wave velocity (surrogate for LV filling pressures) and tricuspid regurgitation peak velocity (to estimate pulmonary systolic pressures) were significantly lower in participants with higher quartiles of magnesium intake/kg.
Echocardiographic Parameters
Discussion
In the largest cardiovascular cohort of blacks to date, magnesium intake was inversely related to future HF hospitalization in both men and women followed for 5 years. To our knowledge, these findings are the first to relate magnesium intake to incident HF events in a cohort of mostly non-HF patients (<3% of our baseline population) with normal LV systolic function. Results remained consistent when adjusting for dietary factors and when individuals with previously diagnosed HF were excluded. Quartiles of magnesium intake/kg were also inversely related to Doppler peak mitral E-wave velocity (a surrogate for diastolic function) and tricuspid regurgitation peak velocity (an estimate of pulmonary systolic pressures) but unrelated to systolic function.
Potential mechanisms of how magnesium intake is related to HF hospitalizations remain to be clarified but are likely multifactorial. Magnesium is a principal intracellular cation that affects muscle relaxation 17, 35, 36 and may improve diastolic dysfunction as shown previously in intravenous supplementation, 37 and in the current study, we found that magnesium intake was related to lower peak mitral E-wave velocity. Equally important, we also observed that magnesium intake was inversely related to estimates of pulmonary systolic pressures. These findings support the notions that magnesium intake may have either a direct effect on the pulmonary vasculature or an indirect effect as a result of improvement in diastolic function, which should be pursued further in future mechanistic work. In contrast, we did not find a significant relation between magnesium intake and systolic function. This can be because of a lack of statistical power because 92.5% of our study population had a normal LV EF of >55%. In addition, magnesium intake may be related to lower risk of HF hospitalizations because of improvement of blood pressure and glycemic control or lower low-density lipoproteincholesterol levels, which may result in lower prevalence of coronary heart disease. 10, 11, 38 As shown in Table 1 , individuals with higher magnesium intake had lower blood pressure, low-density lipoprotein-cholesterol, and hemoglobin A1c levels, as well as lower prevalence of hypertension and diabetes mellitus. Previous studies have demonstrated that magnesium exerts beneficial effects on the cardiovascular system by enhancing endothelium-dependent vasodilation, improving lipid and glucose metabolism, reducing inflammation, and inhibiting platelet aggregation. 9, [39] [40] [41] Indeed, higher levels of magnesium intake were associated with lower hsCRP levels as also seen in Table 1 .
The magnesium intake of 2.7 to 3.7 mg magnesium intake/kg of body weight or 252.5 to 317.0 mg/d in the middle quartiles of our study cohort is slightly higher than the average consumption of magnesium for blacks of 237 mg/d shown in 2004, 11 yet still slightly below the US recommended daily allowance values of >320 mg of intake for women and far below the 420 mg for men aged 31 to 70 years old. However, even at these below recommended daily allowance values of magnesium intake from the second quartile and thereafter, we found an association with less HF hospitalization risk when compared with the magnesium intake/kg at the lowest quartile (1.8 mg/kg of body weight or 181 mg per day). Although an important finding, these results should not be surprising because recommended daily allowance values were developed for the planning and procurement of food supplies at the population level to provide adequate intake for those with the highest requirements and not necessarily as a threshold below which disease will develop with inadequate intake. 42 As such, recommended daily allowance levels do not take into account biological variability or efficiency of utilization of the nutrient in food sources. In addition, the lack of a significant linear relationship between magnesium intake and HF hospitalization risk in our study may suggest that there is a threshold effect, after which higher magnesium intake levels did not translate into less risk. In our population with a mean age of 55±12 years, we did not see further lowering of the hazards of HF hospitalization after the third quartile of magnesium intake (mean 3.7±0.3 mg/kg or 317±68.5 mg per day).
There are limitations to our study. First, inherent to all observational studies and despite our efforts to adjust for potential confounding, our results may still be biased by residual confounding and by exclusion of a small group of sicker participants for various reasons. However, our study sample still has adequate representation of participants with distinct comorbidities. More importantly, the exclusion of the sicker participants is likely to bias toward the null hypothesis given less likelihood of incident events. We tried to conduct sensitivity analyses accounting for calcium, potassium, total daily water intake, in addition to total energy intake ( Table 2 , models 3-6) and found the results to be consistent with the main findings. Second, serum magnesium levels were not available, and the general limitations of the FFQ as a dietary assessment tool cannot be overlooked, including its reliance on memory, reporting completeness and over-or underestimation of nutrients and of total energy intake, especially in obese subjects. 43 Ideally, calibration of nutrient/caloric intake with biomarkers to validate the questionnaire findings would be valuable to overcome these limitations. 16, 44 Finally, detailed data involving clinical presentation of HF and mode of death were unavailable to allow us to elucidate potential mechanisms, and adjudication of HF events did not start until 2005; therefore, we could have underestimated the relationship between dietary magnesium and HF hospitalizations. Given these limitations, our results should be considered as hypothesis generating.
In conclusion, we report that quartiles of magnesium intake/kg body mass predicted future HF events and an intake <2.3 mg/kg weight (≈181 mg/d) may represent a risk factor for future HF hospitalizations. Additional studies are needed to test whether serum magnesium concentration or intake (or both) predict risk of HF.
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